| 000 | 01048 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513125609.0 | ||
| 264 | 0 | _c19971023 | |
| 008 | 199710s 0 0 eng d | ||
| 022 | _a0362-5664 | ||
| 024 | 7 |
_a10.1097/00002826-199408000-00002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWoofter, M J | |
| 245 | 0 | 0 |
_aSafety of long-term levodopa therapy in malignant melanoma. _h[electronic resource] |
| 260 |
_bClinical neuropharmacology _cAug 1994 |
||
| 300 |
_a315-9 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xcomplications |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 700 | 1 | _aManyam, B V | |
| 773 | 0 |
_tClinical neuropharmacology _gvol. 17 _gno. 4 _gp. 315-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00002826-199408000-00002 _zAvailable from publisher's website |
| 999 |
_c9294005 _d9294005 |
||